Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-068602
Filing Date
2025-05-12
Accepted
2025-05-12 08:19:03
Documents
79
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mbx-20250331.htm   iXBRL 10-Q 1574649
2 EX-10.1 mbx-ex10_1.htm EX-10.1 121464
3 EX-31.1 mbx-ex31_1.htm EX-31.1 17255
4 EX-31.2 mbx-ex31_2.htm EX-31.2 17383
5 EX-32.1 mbx-ex32_1.htm EX-32.1 16633
  Complete submission text file 0000950170-25-068602.txt   7487561

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mbx-20250331.xsd EX-101.SCH 1119578
82 EXTRACTED XBRL INSTANCE DOCUMENT mbx-20250331_htm.xml XML 1293669
Mailing Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032
Business Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032 3179893100
MBX Biosciences, Inc. (Filer) CIK: 0001776111 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42272 | Film No.: 25932713
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)